Press Releases Check out the latest news from Tavanta December 06, 2018 Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer May 02, 2018 Best in Class Erectile Dysfunction Drug – DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99 October 05, 2017 DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company’s novel Super-API technology platform December 19, 2016 DRGT’s novel Celecoxib composition – opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market December 14, 2016 Dr. Philip Kantoff – leading expert in clinical oncology and prostate cancer joins DRGT as Senior Clinical Advisor December 09, 2016 DRGT’s novel Abiraterone Acetate composition provides opportunity for dose reduction and increased efficacy in prostate cancer June 23, 2015 Quotient Clinical Begins Prostate Cancer Project for Druggability Technologies December 05, 2013 Druggability Technologies enters into a strategic collaboration with Bayer HealthCare <<12
